ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2026
Disruption of RNA metabolism and its impact on protein homeostasis.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Repeat-associated disorders arise from expansions of nucleotide repeats in coding or non-coding regions, producing RNAs that accumulate and disrupt cellular homeostasis through mechanisms collectively termed RNA repeat toxicity. This process complements proteotoxicity in coding-region expansions and is increasingly recognized as a major contributor to pathogenesis. Expanded repeat RNAs form stable secondary structures that sequester RNA-binding proteins (RBPs), such as Muscleblind-like, alter splicing and activate small RNA pathways, broadly impacting gene expression. Myotonic dystrophy type 1 (DM1) exemplifies RNA-mediated toxicity, with expanded CUG repeats in the DMPK 3' untranslated region driving nuclear foci formation, RBP sequestration and transcriptome-wide changes. Beyond RNA processing defects, DM1 exhibits systemic dysfunction, notably affecting energy metabolism and mitochondrial function, which recent evidence suggests may be disrupted early and progressively during disease development. These metabolic changes intersect with proteostasis failure, amplifying cellular stress and contributing to systemic pathology. A deeper understanding of the molecular networks that drive metabolic and mitochondrial dysfunction, and their role in proteostasis collapse, will be critical for elucidating disease onset and progression. This knowledge will enable the identification of novel therapeutic targets and biomarkers, offering strategies that go beyond RNA-centric approaches to restore cellular homeostasis in repeat-based disorders. This article is part of the Theo Murphy meeting issue 'ProteostaSys: a systems view of proteostasis'.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.